These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 18166843)

  • 21. Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non-small cell lung cancer.
    Hirsh V; Soulieres D; Duclos M; Faria S; Del Vecchio P; Ofiara L; Ayoub JP; Charpentier D; Gruber J; Portelance L; Souhami L
    J Thorac Oncol; 2007 Oct; 2(10):927-32. PubMed ID: 17909355
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized phase II trial using two different treatment schedules of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer.
    Masters GA; Argiris AE; Hahn EA; Beck JT; Rausch PG; Ye Z; Monberg MJ; Bloss LP; Curiel RE; Obasaju CK
    J Thorac Oncol; 2006 Jan; 1(1):19-24. PubMed ID: 17409822
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
    Gray HJ; Bell-McGuinn K; Fleming GF; Cristea M; Xiong H; Sullivan D; Luo Y; McKee MD; Munasinghe W; Martin LP
    Gynecol Oncol; 2018 Mar; 148(3):507-514. PubMed ID: 29352572
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gemcitabine/carboplatin in patients with metastatic non-small-cell lung cancer: phase II study of 28-day and 21-day schedules.
    Obasaju CK; Ye Z; Bloss LP; Monberg MJ; Curiel RE
    Clin Lung Cancer; 2005 Nov; 7(3):202-7. PubMed ID: 16354316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer.
    Davies AM; Ho C; Metzger AS; Beckett LA; Christensen S; Tanaka M; Lara PN; Lau DH; Gandara DR
    J Thorac Oncol; 2007 Dec; 2(12):1112-6. PubMed ID: 18090584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial.
    Lara PN; Koczywas M; Quinn DI; Lenz HJ; Davies AM; Lau DH; Gumerlock PH; Longmate J; Doroshow JH; Schenkein D; Kashala O; Gandara DR
    J Thorac Oncol; 2006 Feb; 1(2):126-34. PubMed ID: 17409841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I study of second-line chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer.
    Oka M; Fukuda M; Nagashima S; Fukuda M; Kinoshita A; Soda H; Doi S; Narasaki F; Suenaga M; Takatani H; Nakamura Y; Kawabata S; Tsurutani J; Kanda T; Kohno S
    Cancer Chemother Pharmacol; 2001 Dec; 48(6):446-50. PubMed ID: 11800024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.
    Ma C; Mandrekar SJ; Alberts SR; Croghan GA; Jatoi A; Reid JM; Hanson LJ; Bruzek L; Tan AD; Pitot HC; Erlichman C; Wright JJ; Adjei AA
    Cancer Chemother Pharmacol; 2007 Feb; 59(2):207-15. PubMed ID: 16763792
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I study of gemcitabine and carboplatin in non-small cell lung cancer.
    Carmichael J; Allerheiligen S; Walling J
    Semin Oncol; 1996 Oct; 23(5 Suppl 10):55-9. PubMed ID: 8893883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I/II study of gemcitabine and vinorelbine plus cisplatin in non-small cell lung cancer.
    Esteban E; Fra J; Sala M; Carrasco J; Corral N; Vieitez JM; Estrada E; Palacio I; Buesa JM; Lacave AJ
    Invest New Drugs; 2002 Aug; 20(3):317-26. PubMed ID: 12201494
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activity of bortezomib in advanced non-small-cell lung cancer.
    Reddy KG
    Clin Lung Cancer; 2004 Nov; 6(3):141-2. PubMed ID: 15555213
    [No Abstract]   [Full Text] [Related]  

  • 32. Decreased myelotoxicity of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) with cisplatin infusion on day 15.
    Cortesi E; Ramponi S; Corona M; Moscetti L; Grifalchi F; Oliva A; Lembo A; Gasperoni S; Padovani A
    Lung Cancer; 2001; 31(2-3):271-6. PubMed ID: 11165407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New triplet chemotherapy combination with carboplatin, paclitaxel and gemcitabine plus amifostine support in advanced non small cell lung cancer: a phase II study.
    Illiano A; Barletta E; De Marino V; Battiloro C; Barzelloni M; Scognamiglio F; Rossi N; Zampa G; De Bellis M; Gridelli C
    Anticancer Res; 2000; 20(5C):3999-4003. PubMed ID: 11268491
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest radiation in patients with stage III non-small cell lung cancer.
    Argiris A; Liptay M; LaCombe M; Marymont M; Kies MS; Sundaresan S; Masters G
    Lung Cancer; 2004 Aug; 45(2):243-53. PubMed ID: 15246197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer.
    Bajetta E; Stani SC; De Candis D; Zaffaroni N; Zilembo N; Cortinovis D; Aglione S; Mariani L; Formisano B; Bidoli P
    Ann Oncol; 2003 Feb; 14(2):242-7. PubMed ID: 12562651
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized multicentric phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer GFPC 99-01 study (Groupe français de pneumo-cancérologie).
    Thomas P; Robinet G; Gouva S; Fournel P; Léna H; Le Caer H; Perol M; Berard H; Bombaron P; Vergnenegre A; Kleisbauer JP;
    Lung Cancer; 2006 Jan; 51(1):105-14. PubMed ID: 16310886
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
    Kosmas C; Tsavaris N; Syrigos K; Koutras A; Tsakonas G; Makatsoris T; Mylonakis N; Karabelis A; Stathopoulos GP; Kalofonos HP
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):51-9. PubMed ID: 16622691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II study of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer.
    Wang LR; Huang MZ; Zhang GB; Xu N; Wu XH
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):601-7. PubMed ID: 17549479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gemcitabine and low dose carboplatin in the treatment of elderly patients with advanced non-small cell lung cancer.
    Maestu I; Gómez-Aldaraví L; Torregrosa MD; Camps C; Llorca C; Bosch C; Gómez J; Giner V; Oltra A; Albert A
    Lung Cancer; 2003 Dec; 42(3):345-54. PubMed ID: 14644523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line.
    Mortenson MM; Schlieman MG; Virudachalam S; Bold RJ
    Cancer Chemother Pharmacol; 2004 Oct; 54(4):343-53. PubMed ID: 15197486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.